United States Hepatocellular Carcinoma Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global Hepatocellular Carcinoma (HCC) Market was valued at USD 977 million in 2022. It is projected to reach USD 2.4 billion by 2031, growing at a CAGR of 12.2% (2024-2031).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/hepatocellular-carcinoma-market?sb

Key Development:

United States: Recent Hepatocellular Carcinoma Developments

✅ In December 2025, BeOne Medicines Ltd. secured U.S. FDA Fast Track designation for its HCC‐targeted bispecific antibody BGB‐B2033, bolstering its strategic value and positioning it as an attractive acquisition or partnership candidate in the oncology space; this regulatory milestone often accelerates M&A interest.

✅ In November 2025, Can‐Fite BioPharma reported ongoing Phase III HCC trial progress for Namodenoson, with the candidate maintaining Orphan Drug and Fast Track designations by the FDA and the company completing additional funding rounds to support HCC clinical work.

✅ In November 2025, global diagnostics and cancer‐screening leader Abbott agreed to acquire Exact Sciences in a $21 billion deal, strengthening its precision oncology and early cancer detection portfolio a move that underscores broader consolidation in cancer tech relevant to liver cancer diagnostics and risk stratification.

✅ In April 2025, the U.S. Food and Drug Administration approved the combination of nivolumab (Opdivo) with ipilimumab (Yervoy) as a first‐line treatment for unresectable or metastatic hepatocellular carcinoma, offering a new immune‐checkpoint inhibitor option in frontline care.

✅ In late 2025, multiple HCC clinical trials are actively recruiting in the U.S., including immunotherapy and combination regimens such as durvalumab ± tremelimumab, highlighting expanded research activity in advanced liver cancer.

✅ In October 2025, Zymeworks reported that its first patient has been dosed in a Phase 1 trial of ZW251, an antibody‐drug conjugate for HCC, while also hitting development milestones tied to collaboration funding with Johnson & Johnson Innovative Medicine.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=hepatocellular-carcinoma-market

Japan: Recent Hepatocellular Carcinoma Developments

✅ In November 2025, Eisai updated the status of its Phase III LEAP‐012 trial for unresectable/locally advanced HCC, reinforcing Japan's role in global immuno‐oncology and combination therapy development for liver cancer.

✅ In November 2025, industry reports spotlight novel FGFR4 inhibitors showing strong antitumor activity in HCC preclinical evaluations, signaling future therapeutic directions emerging from Japanese and global research collaborations.

✅ In late 2025, ongoing Japanese clinical trial registries list multiple HCC studies, including Rilvegostomig entering Phase III and AZD9793 in Phase I/II, demonstrating continued domestic trial activity against hepatocellular carcinoma.

✅ In late 2025, Japanese regulatory and academic sites reaffirm that multicenter HCC immunotherapy and combination trials using established agents continue recruitment and protocol development, underscoring sustained R&D momentum.

Key Players:

=> Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd, Polaris Pharmaceuticals Inc., Creative Diagnostics, Harbour BioMed and Merck & Co. Inc.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/hepatocellular-carcinoma-market?sb

Key Segments:

By Treatment

Chemotherapy leads with 40% share, driven by its widespread use across multiple cancer types, established protocols, and ongoing R&D for combination therapies. Surgery accounts for 25%, supported by early-stage cancer detection, minimally invasive techniques, and advanced surgical procedures. Brachytherapy holds 15%, fueled by precision radiation therapy demand and adoption in prostate, cervical, and breast cancers. Local Ablation Therapy represents 10%, driven by non-invasive alternatives for liver, kidney, and lung tumors. Others account for 10%, including emerging immunotherapies, targeted therapies, and novel treatment approaches.

By End-User

Hospitals dominate with 50% share, owing to availability of multidisciplinary oncology services, advanced treatment infrastructure, and high patient footfall. Cancer Rehabilitation Centers hold 20%, driven by growing awareness of post-treatment care, physiotherapy, and patient support services. Clinics represent 15%, supported by outpatient care, localized treatment, and follow-up services. Others account for 15%, including homecare services and specialized cancer treatment facilities.

By Region

North America - 38% Share
North America leads with 38%, driven by advanced healthcare infrastructure, high prevalence of cancer, robust R&D, and adoption of cutting-edge treatment modalities in the U.S. and Canada.

Europe - 30% Share
Europe holds 30%, supported by well-established oncology centers, government initiatives, and strong adoption of modern therapies in Germany, U.K., France, and Italy.

Asia Pacific - 22% Share
Asia Pacific accounts for 22%, fueled by increasing cancer prevalence, growing healthcare investments, and rising awareness in China, Japan, India, and Southeast Asia.

Latin America - 6% Share
Latin America holds 6%, driven by expanding healthcare infrastructure, increasing cancer awareness, and adoption of conventional and advanced treatment modalities in Brazil and Mexico.

Middle East & Africa - 4% Share
Middle East & Africa represent 4%, supported by urban healthcare expansion, government initiatives for cancer treatment, and growing adoption of advanced therapies in GCC countries, South Africa, and North Africa.

FAQ

What is the current size of the Hepatocellular Carcinoma Market?

A: In 2022, the Hepatocellular Carcinoma Market was valued at USD 977 million , reflecting its strong industry presence.

Q2: How large is the Hepatocellular Carcinoma Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Hepatocellular Carcinoma Market will grow to around USD 2.4 billion , demonstrating significant expansion.

Q3: What is the growth rate of the Hepatocellular Carcinoma Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 12.2% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.